Neurocrine Reports Positive Results From Phase III Kinect 3 Study Of NBI-98854

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. The Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

During the six-week placebo-controlled treatment period NBI-98854 was generally well tolerated. Neurocrine said the frequency of adverse events was similar among all treatment groups and treatment emergent adverse effects were consistent with those of prior studies.

"The results of this Kinect 3 study demonstrate the potential of NBI-98854 to be a safe and effective treatment for patients suffering from the debilitating effects of tardive dyskinesia," said Christopher O'Brien, Chief Medical Officer of Neurocrine.